Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

NBY NovaBay Pharmaceuticals Inc New

0,0782

0,0012 (1,56%)

27 Avr 2024 - Fermé

Retardé de 15 minutes

Form D - Notice of Exempt Offering of Securities

NovaBay Pharmaceuticals (AMEX:NBY)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024

Plus de graphiques de la Bourse NovaBay Pharmaceuticals

NovaBay Pharmaceuticals (AMEX:NBY)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024

Plus de graphiques de la Bourse NovaBay Pharmaceuticals

Actualités NovaBay Pharmaceuticals Inc New

NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
Lundi 22 Avril 2024 ( il y a 5 jours) • Business Wire

NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
Samedi 20 Avril 2024 ( il y a 1 semaine) • Business Wire

NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
Mercredi 17 Avril 2024 ( il y a 1 semaine) • Business Wire

NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
Mardi 26 Mars 2024 ( il y a 1 mois) • Business Wire

NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
Lundi 25 Mars 2024 ( il y a 1 mois) • Business Wire

NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
Jeudi 14 Mars 2024 ( il y a 1 mois) • Business Wire

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Mercredi 14 Février 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Mardi 6 Février 2024 ( il y a 3 mois) • Edgar (US Regulatory)

NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales
Mardi 30 Janvier 2024 ( il y a 3 mois) • Business Wire

Form 8-K - Current report
Mercredi 10 Janvier 2024 ( il y a 4 mois) • Edgar (US Regulatory)

NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
Mardi 9 Janvier 2024 ( il y a 4 mois) • Business Wire

Form D - Notice of Exempt Offering of Securities
Jeudi 4 Janvier 2024 ( il y a 4 mois) • Edgar (US Regulatory)

Plus d'articles sur NovaBay Pharmaceuticals Inc New

Lvmh Moet Hennessy Louis...

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales